| Project Number | pCODR 10164 |
|---|---|
| Brand Name | Ninlaro |
| Generic Name | Ixazomib |
| Strength | 4 mg, 3 mg and 2.3 mg |
| Tumour Type | Myeloma |
| Indication | Multiple Myeloma (2nd-beyond) |
| Funding Request | In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Review Status | Pending |
| Pre Noc Submission | No |
| NOC Date | August 4, 2016 |
| Manufacturer | Takeda Canada Inc. |
| Submitter | Takeda Canada Inc. |
| Submission Date (Target Date) | November 30, 2018 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline (target date based on target submission date) ‡ | December 14, 2018 |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
